<DOC>
	<DOCNO>NCT00255749</DOCNO>
	<brief_summary>RATIONALE : Epoetin alfa may cause body make red blood cell . It use treat anemia cause cancer chemotherapy . PURPOSE : This randomized phase II trial study well epoetin alfa work treat patient anemia undergoing chemotherapy cancer .</brief_summary>
	<brief_title>Epoetin Alfa Treating Patients With Anemia Who Are Undergoing Chemotherapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy , term maintenance target hemoglobin hematocrit level , interval dose epoetin alfa patient anemia undergo chemotherapy nonmyeloid cancer . - Determine safety drug patient . Secondary - Determine quality life patient treated drug . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . - Arm I ( early intervention ) : Patients receive epoetin alfa subcutaneously day 1 . Treatment repeat every 21 day 5 course . - Arm II ( standard intervention ) : Patients receive epoetin alfa arm I hemoglobin level ≤ 10.5 g/dL . Quality life assess prior start study treatment , week 7 study treatment , completion study treatment . After completion study treatment , patient follow 4 week . PROJECTED ACCRUAL : A total 180 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonmyeloid cancer No history myelodysplasia Baseline hemoglobin 1112 g/dL No anemia due factor cancer chemotherapy ( e.g. , iron , cyanocobalamin [ vitamin B_12 ] , folate deficiency , hemolysis , gastrointestinal bleeding ) Receiving chemotherapy meet follow criterion : Administered weekly OR every 3 week Must begin chemotherapy first day study treatment No known , untreated CNS metastases PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic See Disease Characteristics Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Iron transferrin saturation &gt; 20 % No history chronic hypercoagulable disorder ( e.g. , activate protein C resistance , anticardiolipin disorder , protein C deficiency , protein S deficiency ) Hepatic Bilirubin &lt; 2.0 mg/dL SGPT ≤ 3 time upper limit normal Renal Creatinine ≤ 1.5 mg/dL No significant , uncontrolled genitourinary disease dysfunction Cardiovascular No uncontrolled cardiac arrhythmia past 6 month No uncontrolled hypertension No deep vein thrombosis , ischemic stroke , arterial venous thrombotic event Superficial thromboses allow No significant , uncontrolled cardiovascular disease dysfunction Pulmonary No significant , uncontrolled pulmonary disease dysfunction No pulmonary emboli Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No infection require hospitalization antibiotic past 14 day No known hypersensitivity mammalian cellderived product human albumin No new onset ( past 3 month ) poorly control seizures No active malignancy except basal cell carcinoma carcinoma situ Not employee investigator study center family member employee investigator No significant , uncontrolled neurological , endocrine , gastrointestinal disease dysfunction PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy More 3 month since prior erythropoietic agent ( e.g. , epoetin alfa , darbepoetin alfa , geneactivated erythropoietin ) More 4 week since prior pack red blood cell transfusion No concurrent stem cell harvest bone marrow No concurrent interleukin11 No concurrent erythropoietic agent Chemotherapy See Disease Characteristics No concurrent highdose chemotherapy stem cell transplantation Radiotherapy No concurrent nonpalliative radiotherapy Surgery More 2 week since prior major surgery Other At least 1 month since prior investigational agent device No concurrent highdose IV iron supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>anemia</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
</DOC>